APR-1051 在晚期实体瘤患者中的研究 (ACESOT-1051)
一项开放标签、多中心、首次人体研究,旨在评估 APR-1051 在晚期实体瘤患者中的安全性、耐受性、药代动力学和初步疗效
The purpose of this study is to assess the safety and effectiveness of APR-1051 through the performance of a Phase 1, open-label, safety, PK, and preliminary efficacy study of oral APR-1051 in patients with advanced solid tumors.
研究概览
研究类型
注册 (估计的)
阶段
- 阶段1
联系人和位置
学习联系方式
- 姓名:Senior Medical Advisor
- 电话号码:215-948-4119
- 邮箱:info@aprea.com
学习地点
-
-
New Jersey
-
New Brunswick、New Jersey、美国、08903
- 招聘中
- Rutgers Cancer Institute
-
首席研究员:
- Sanjay Goel, MD
-
接触:
- Kassie DiOrio
- 邮箱:kassie.diorio@rutgers.edu
-
接触:
- Mohammad Ghalib
- 邮箱:mhg68@cinj.rutgers.edu
-
-
Ohio
-
Cleveland、Ohio、美国、44195
- 招聘中
- Cleveland Clinic
-
接触:
- Cancer Answer Line
- 电话号码:866-223-8100
-
首席研究员:
- Joesph Wooley, MD
-
Cleveland、Ohio、美国、44106
- 招聘中
- University Hospitals, Cleveland Medical Center
-
首席研究员:
- Amit Mahipal, MD
-
接触:
- Amit Mahipal, MD
- 电话号码:216-844-6031
- 邮箱:Amit.Mahipal@UHHospitals.org
-
-
Texas
-
Houston、Texas、美国、77030
- 招聘中
- MD Anderson Cancer Center (MDACC)
-
首席研究员:
- Timothy Yap, MD
-
接触:
- Jessica Rhudy
-
接触:
- 电话号码:713-745-5474
- 邮箱:jrhudy@mdanderson.org
-
Houston、Texas、美国、77054
- 招聘中
- NEXT Oncology- Houston
-
首席研究员:
- Jennifer Segar, MD
-
接触:
- Emma Morales
- 电话号码:832-384-7912
- 邮箱:emorales@nextoncolgy.com
-
Irving、Texas、美国、75039
- 招聘中
- NEXT Oncology -Dallas
-
首席研究员:
- Shiraj Sen, MD
-
接触:
- Rebecca Popiel
- 电话号码:972-893-8800
- 邮箱:rpopiel@nextoncology.com
-
San Antonio、Texas、美国、78229
- 招聘中
- NEXT Oncology -San Antonio
-
首席研究员:
- David Sommerhalder, MD
-
接触:
- Jordan Georg
- 电话号码:210-580-9500
- 邮箱:jgeorg@nextoncology.com
-
-
Virginia
-
Fairfax、Virginia、美国、22031
- 招聘中
- NEXT Oncology -Virginia
-
接触:
- Maybelle De La Rosa
- 电话号码:703-783-4518
- 邮箱:mdelarosa@nextoncology.com
-
首席研究员:
- Mohamad Salkeni, MD, FRCPC
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Age ≥ 18 years
- Diagnosis of advanced/metastatic solid tumor
- Measurable or evaluable disease per RECIST version 1.1 (radiographic disease progression per PCWG3 criteria for patients with mCRPC)
- Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1 or Karnofsky Performance Status (KPS) ≥ 70%
- Patients must have recovered to Grade 1 or baseline levels from toxicity or adverse events related to prior treatment for their cancer, excluding Grade ≤ 2 neuropathy, alopecia, or skin pigmentation
- Adequate bone marrow and organ function
- Women of child-bearing potential (WOCBP) or men of child-fathering potential must agree to use adequate contraception prior to study entry
Exclusion Criteria:
- Patient has had prior systemic anti-cancer therapy (cytotoxic chemotherapy, immunotherapy, targeted therapy) within 3 weeks (6 weeks in cases of mitomycin C, nitrosourea, lomustine) or at least 5 half-lives (whichever is shorter, but no less than 2 weeks) prior to Day 1
- Prior radiation therapy at the target lesion unless there is evidence of disease progression. If patient has had prior radiation therapy for disease progression, see Exclusion Criterion 1 for allowed interval between radiotherapy and Day 1 and recovery of AEs
- Treatment with any investigational agent administered within 30 days or 5 half-lives, whichever is shorter, before the first dose of APR-1051
- Major surgery within 21 days prior to Day 1
- Concomitant treatment with other anti-cancer therapy, including chemotherapy, immunotherapy, biological therapy, radiation therapy (except palliative local radiation therapy), or other novel anti-cancer agents. Note: endocrine therapy for breast and prostate cancer is allowed along with agents to treat or prevent skeletal related events (zoledronic acid, pamidronate, denosumab)
- Subjects with active (uncontrolled, metastatic) second malignancies or requiring therapy
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:APR-1051
Dose Escalation based on BOIN Design |
WEE1 Inhibitor |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Treatment-related adverse events
大体时间:Day 1 to 28, each cycle is 28 days
|
|
Day 1 to 28, each cycle is 28 days
|
|
Recommended dose of APR-1051
大体时间:Day 1 to 28, each cycle is 28 days
|
•Part 1 dose escalation: Recommended Phase 2 Dose (RP2D) of APR-1051 monotherapy [Time frame: Day 1 through to start of dose expansion phase]. The RP2D of will be determined based on review of safety, tolerability, pharmacokinetics/pharmacodynamics, and preliminary efficacy data |
Day 1 to 28, each cycle is 28 days
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Pharmacokinetics: Cmax/Cmin of APR-1051
大体时间:Day 1 to 112
|
Plasma concentration of APR-1051: maximum (Cmax), minimum (Cmin) |
Day 1 to 112
|
|
Pharmacokinetics: Tmax of APR-1051
大体时间:Day 1 to 112
|
Time to peak plasma concentration of APR-1051 (Tmax) |
Day 1 to 112
|
|
Pharmacokinetics: AUC of APR-1051
大体时间:Day 1 to 112
|
Area under plasma versus time curve (AUC) of APR-1051 max) |
Day 1 to 112
|
|
Pharmacokinetics: t1/2 of APR-1051
大体时间:Day 1 to 112
|
Half-life of APR-1051 (t1/2) |
Day 1 to 112
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- APR-1051-001
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.